{name}
{subtitle}
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~80 mi. (Pozzuoli, Italy, +226 more cities)
facility
Presidio Ospedaliero S. Maria Delle Grazie-U.O.C. ONCOLOGIA ( Site 0802)
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
city
~80 mi. (Pozzuoli, Italy, +93 more cities)
facility
Presidio Ospedaliero Santa Maria delle Grazie ( Site 0599)
condition
Bladder Carcinoma, +1 more condition
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +3 more types
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~92 mi. (Naples, Italy, +192 more cities)
facility
University of Naples Federico II
biomarker
ER Positive, +1 more biomarker
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002)
city
~92 mi. (Naples, Italy, +76 more cities)
facility
Azienda Ospedaliera Dei Colli-U.O.C Pneumologia Oncologica DH PNL ONC ( Site 1308)
drug
docetaxel, +1 more drug
drug type
chemotherapy, +1 more type
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET) (MK-6482-015)
city
~92 mi. (Naples, Italy, +29 more cities)
facility
University of Naples Federico II-Dipartimento di Medicina Clinica e Chirurgia ( Site 0704)
condition
Pancreatic Neuroendocrine Tumor, +1 more condition
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
city
~92 mi. (Naples, Italy, +44 more cities)
facility
National Cancer Institute
biomarker
BCL2 Fusion, +2 more biomarkers
condition
Diffuse Large B-Cell Lymphoma, +3 more conditions
drug
cisplatin, +5 more drugs
drug type
chemotherapy, +3 more types
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~98 mi. (Rome, Italy, +144 more cities)
facility
Fondazione Policlinico Universitario A. Gemelli ( Site 1414)
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
city
~98 mi. (Rome, Italy, +147 more cities)
facility
Istituto Nazionale Tumori Regina Elena ( Site 0540)
condition
Cervical Adenocarcinoma, +2 more conditions
drug
brachytherapy, +3 more drugs
drug type
chemotherapy, +2 more types
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
city
~98 mi. (Rome, Italy, +127 more cities)
facility
Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 214910
drug
azacitidine, +2 more drugs
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
city
~98 mi. (Rome, Italy, +189 more cities)
facility
Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 219087, +1 more facility
biomarker
del(11)(q10), +27 more biomarkers
drug
navitoclax, +1 more drug
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
city
~98 mi. (Rome, Italy, +165 more cities)
facility
Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 219083
biomarker
del(11)(q10), +27 more biomarkers
drug
navitoclax, +1 more drug